Business Segments Cizzle Biotechnology Holdings Plc
Equities
PSL
GB00BNG2VN02
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.550 GBX | 0.00% |
|
+10.71% | - |
| 04/02 | Cizzle secures Canadian patent for lung cancer test format | AN |
| 04/02 | Cizzle Biotechnology Lung Cancer Test Secures Patent in Canada | MT |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Gene Research and Development | ||||||||||
Development of Tests for The Early Detection of Lung Cancer | - | - | - | - | - | |||||
Total Assets | 10T | 11.55L | 27.85L | 16.93L | 5L | |||||
Income Tax Expense | - | -37T | -51T | -46T | -21T | |||||
CAPEX | - | -2L | - | - | - | |||||
EBT | -14T | -39.58L | -10L | -17.63L | -21.87L | |||||
Gross Profit | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Net Income | -14T | -39.21L | -9L | -17.17L | -21.66L |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
United Kingdom | - | - | - | - | - | |||||
Total Assets | 10T | 11.55L | 27.85L | 16.93L | 5L | |||||
Income Tax Expense | - | -37T | -51T | -46T | -21T | |||||
CAPEX | - | -2L | - | - | - | |||||
Gross Profit | - | - | - | - | - | |||||
Net Income | -14T | -39.21L | -9L | -17.17L | -21.66L | |||||
EBT | -14T | -39.58L | -10L | -17.63L | -21.87L | |||||
Operating Income | - | - | - | - | - |
- Stock Market
- Equities
- PSL Stock
- Financials Cizzle Biotechnology Holdings Plc
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition